Caption Management, LLC Amylyx Pharmaceuticals, Inc. Call Options Transaction History

Caption Management, LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	BUY	$2.71 - $19.57 $1.15 Million - $8.27 Million	422,800 Added 422.8%	522,800 $1.48 Million
Q4 2023 Feb 14, 2024	SELL	$12.07 - $18.46 $1.43 Million - $2.19 Million	-118,600 Reduced 54.25%	100,000 $1.47 Million
Q3 2023 Nov 14, 2023	SELL	$18.08 - $23.45 $6.46 Million - $8.37 Million	-357,100 Reduced 62.03%	218,600 $4 Million
Q2 2023 Aug 14, 2023	BUY	$20.98 - $31.42 $2.85 Million - $4.26 Million	135,700 Added 30.84%	575,700 $12.4 Million
Q1 2023 May 15, 2023	BUY	$27.71 - $40.93 $12.2 Million - $18 Million	440,000 New	440,000 $12.9 Million
Q3 2022 Nov 14, 2022	SELL	$17.15 - $30.92 $46,304 - $83,484	-2,700 Reduced 1.52%	174,900 $4.92 Million
Q2 2022 Aug 15, 2022	BUY	$6.85 - $19.93 $448,675 - $1.31 Million	65,500 Added 58.43%	177,600 $3.42 Million
Q1 2022 May 13, 2022	BUY	$12.85 - $32.9 $1.44 Million - $3.69 Million	112,100 New	112,100 $1.44 Million

139

46.5M

226K

909K

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $290M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Caption Management, LLC with notifications on news.